GlassScriptPhysician profile
Kay K Mcdaniel
NPI 1538100144
$1,314.44
in general payments reported to CMS, 2019-2025
18 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.38 · 2022: $230 · 2023: $236 · 2024: $322 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $341.71 | 2022-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $188.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $135.35 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $104.10 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.97 | 2021-2025 | Jardiance |
| Cvrx, INC. | $61.08 | 2024 | Barostim Neo System |
| Abbvie INC. | $43.23 | 2023-2025 | |
| Stryker Corporation | $42.27 | 2025 | Clottriever Bold Catheter |
| Phathom Pharmaceuticals, INC. | $41.92 | 2024-2025 | Voquezna |
| Lundbeck LLC | $40.27 | 2024 | Vyepti |
| Abbott Laboratories | $39.45 | 2022 | |
| Pfizer INC. | $38.92 | 2024-2025 | |
| Glaxosmithkline, LLC. | $35.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $32.09 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $31.16 | 2024 | Zepbound, Jardiance, Mounjaro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $27.57 | 2022-2023 | Quviviq |
| Inspire Medical Systems, INC. | $22.56 | 2025 | Inspire |
| Mylan Specialty L.P. | $22.41 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.